Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Salbutamol
Drug ID BADD_D02433
Description Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
Indications and Usage Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm [FDA Label, F3265, F3268].
Marketing Status Not Available
ATC Code R03AC02; R03CC02
DrugBank ID DB01001
KEGG ID D02147
MeSH ID D000420
PubChem ID 2083
TTD Drug ID D0K5CB
NDC Product Code Not Available
Synonyms Albuterol | Salbutamol | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | Ventolin | Sultanol | Albuterol Sulfate | Proventil
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 18559-94-9
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Bone marrow failureBeta-2 adrenergic receptorP07550T52522Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abasia17.02.05.035; 08.01.02.0070.000039%Not Available
Muscle fatigue15.05.03.0060.000026%Not Available
Muscle tightness15.05.03.0070.000026%Not Available
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.001--
Deep vein thrombosis24.01.02.0030.000155%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000007%Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Respiratory tract congestion22.02.07.0030.000052%Not Available
Nasal discomfort22.02.05.0200.000052%Not Available
Pruritus generalised23.03.12.0030.000052%Not Available
Growth retardation15.03.01.0060.000026%
Skin burning sensation17.02.06.009; 23.03.03.0210.000026%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000010%
Pulmonary mass22.02.07.0040.000026%Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000039%Not Available
Paraesthesia oral17.02.06.008; 07.05.03.0030.000064%Not Available
Troponin increased13.04.01.0040.000039%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000013%Not Available
Drug resistance08.06.01.0050.000007%Not Available
Cardiac disorder02.01.01.0030.000034%Not Available
Inflammation08.01.05.0070.000039%Not Available
Lung infection22.07.01.008; 11.01.09.0080.000039%
Mental disorder19.07.01.0020.000064%Not Available
Upper limb fracture15.08.03.018; 12.04.01.0180.000026%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.0490.000026%Not Available
Cardiac fibrillation02.03.02.0210.000026%Not Available
Disease progression08.01.03.038--
Disease recurrence08.01.03.0500.000026%Not Available
Drug intolerance08.06.01.013--Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages